Overview
Cellanome builds an automated platform for live-cell analysis to study single-cell behaviors, interactions, and functions under different conditions at scale. Researchers run iterative live-cell phenotypic and functional assays, observing how individual cells respond to stimuli over time. The platform integrates into existing cell biology workflows as a software-and-instrument solution offered by subscription or licensing, enabling high-throughput data collection across many cells. Compared with traditional bulk methods, it focuses on single-cell detail, scalable data, and easy workflow integration to accelerate discovery in life sciences and medicine.
Work here?Claim your company
Simplify's take
What believers are saying
- June 2026 SEC filing targets $75.9 million, signaling continued investor backing.
- Cellanome showed R3200 at AGBT 2026 and entered full commercialization.
- Multiple U.S. installations and planned Europe and Asia expansion broaden sales opportunities.
What critics are saying
- Cellanome sued U.S. Customs on October 14, 2026, adding legal distraction and costs.
- R3200 requires hardware, assays, and cloud software, slowing adoption versus simpler reagents.
- Single-platform dependence makes a commercialization miss existential before Europe and Asia ramp.
What makes Cellanome unique
- Cellanome's R3200 pairs longitudinal imaging with single-cell transcriptomics from same living cells.
- CellCage micro-enclosures let researchers isolate thousands of live cells and co-cultures.
- Omead Ostadan and Mostafa Ronaghi bring Illumina and sequencing pedigree to cell biology.
Help us improve and share your feedback! Did you find this helpful?
Funding
Industry standards